Article

Real-world antipsychotic treatment practices

University of Texas at San Antonio, San Antonio, Texas, United States
The Psychiatric clinics of North America (Impact Factor: 1.87). 10/2007; 30(3):401-16. DOI: 10.1016/j.psc.2007.04.008
Source: PubMed

ABSTRACT This article examines real-world antipsychotic use in the treatment of schizophrenia by comparing real-world prescribing with medication algorithms and guidelines, by evaluating the evidence underlying recommendations and guidelines, and by examining the roles of side effects and medication adherence in real-world prescribing decisions.

Download full-text

Full-text

Available from: Nancy H Covell, Dec 26, 2014
3 Followers
 · 
185 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.
    01/2014; 2014:904829. DOI:10.1155/2014/904829
  • [Show abstract] [Hide abstract]
    ABSTRACT: The occurrence of treatment nonadherence among patients with schizophrenia is clinically significant. However, studies show that clinicians do not make systematic efforts to identify and monitor it over time. This paper reviews the various tactics for identifying and monitoring adherence behavior. A comprehensive review of published studies comparing typical and atypical antipsychotics in terms of medication adherence yields mixed results at best. Changing forces in the delivery of health care in the United States will promote efforts to improve the recognition of nonadherence in patients with schizophrenia and develop strategies and tactics to decrease the current rates of nonadherence. Such tactics are described in this paper, and emerging best practices are identified. Ultimately, if nonadherence rates are to decrease, it will be necessary to align the incentives of the treater and the treated.
    Current Psychiatry Reports 08/2008; 10(4):359-69. DOI:10.1007/s11920-008-0057-7 · 3.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Poor treatment response in patients with schizophrenia is an important clinical problem, and one possible strategy is concurrent treatment with more than one antipsychotic (polypharmacy). We analyzed the evidence base for this strategy using a translational research model focused on clozapine-antipsychotic polypharmacy (CAP). We considered 3 aspects of the existing knowledge base and translational research: the link between basic science and clinical studies of efficacy, the evidence for effectiveness in clinical research and the implications of research for the health care delivery system. Although a rationale for CAP can be developed from receptor pharmacology, there is little available preclinical research testing these concepts in animal models. Randomized clinical trials of CAP show minimal or no benefit for overall severity of symptoms. Most studies at the level of health services are limited to estimates of CAP prevalence and some suggestion of increased costs. Increasing use of antipsychotic polypharmacy in general may be a factor contributing to the under-utilization of clozapine and long delays in initiating clozapine monotherapy. Translational research models can be applied to clinical questions such as the value of CAP. Better linkage between the components of translational research may improve the appropriate use of medications such as clozapine in psychiatric practice.
    Journal of psychiatry & neuroscience: JPN 11/2009; 34(6):433-42. · 7.49 Impact Factor